Combo product GMPs
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers of combination products should consult FDA's Office of Combination Products for assistance on good manufacturing practices, according to office director Mark Kramer. Although the office's role in designating new technologies as devices, drugs or biologics is well-known, "we need to make sure we don't forget [postmarket issues]. As soon as you have your designation, you should start thinking about which GMPs you need," Kramer explained at the PDA/FDA Conference in Washington, D.C. Sept. 8. Between December and June, Kramer noted, the office responded to nine requests for designation - all within the statutory 60-day timeframe; one request is pending. The office has six staff and one opening, but eventually may employ 10 people (1"The Gray Sheet" April 7, 2003, p. 11)...
You may also be interested in...
Combo Product Requests For Designation: More Than A Premarket Tool?
Combination product postmarket issues, including decisions about what type of quality regulations will be required, may sometimes be negotiated as part of a request for designation (RFD), FDA confirms
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.